Skip to content

The impact of lung microbiota on CD4/CD8 T lymphocytes and the efficacy of immunotherapy

The impact of lung microbiota on CD4/CD8 T lymphocytes and the efficacy of immunotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113496
Enrollment
Unknown
Registered
2025-11-28
Start date
2024-10-17
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Observation group:None

Sponsors

Tianjin Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 30-85 years, no contraindications for bronchoscopy surgery; 2. All patients have not undergone bronchoscopy examination before; 3. Complete clinical case information, able to be regularly admitted for efficacy evaluation; 4. Should have at least one measurable lesion.

Exclusion criteria

Exclusion criteria: 1. Tumors combined with obstructive pneumonia, bronchial asthma, tuberculosis, COPD, AIDS, diabetes, idiopathic pulmonary fibrosis, and other diseases that may affect the pulmonary microbiome characteristics; 2. Patients with a history of dust exposure or other special exposure history; 3. No use of antibiotics, corticosteroid therapy, cytokine-related drugs (such as interleukins, interferons, etc.), methotrexate, immunosuppressive cytotoxic drugs, or high-dose probiotic supplements within 3 days prior to admission; 4. Bronchoscopy examination and brushing procedures not performed under sterile conditions or contaminated specimens; 5. Incomplete clinical information.

Design outcomes

Primary

MeasureTime frame
CD4/CD8;

Secondary

MeasureTime frame
Pulmonary microbiota;

Countries

China

Contacts

Public ContactYajing Li

Tianjin Chest Hospital

17612217825@163.com+86 182 2290 4053

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026